SCHEMBL1543435

SCHEMBL1543435

CC(C)(C)c1cc(Br)c(O)c(-c2ccc[nH]c2=O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
PLA2G1B P04054 1/20 0.40
NFKB1 P19838 1/20 0.40
CASP3 P42574 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ATG4B Q9Y4P1 1/20 0.40
HIF1A Q16665 3/20 0.38
CYP2C9 P11712 3/20 0.38
CYP1A2 P05177 3/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C19 P33261 2/20 0.38
TSHR P16473 3/20 0.38
HSD17B10 Q99714 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1543110 0.87 NPC1 (0.45) ALDH1A1NPC1RAB9APLA2G1BNFKB1
SCHEMBL1542849 0.86 NPC1 (0.41) ALDH1A1NPC1RAB9APLA2G1BNFKB1
SCHEMBL1542933 0.83 AKR1C2 (0.38) ALDH1A1NPC1RAB9APLA2G1BNFKB1
SCHEMBL1543258 0.83 ALDH1A1 (0.38) ALDH1A1NPC1RAB9APLA2G1BNFKB1
SCHEMBL1542786 0.82 NPC1 (0.39) ALDH1A1NPC1RAB9APLA2G1BNFKB1
SCHEMBL1542954 0.81 DAO (0.36) ALDH1A1NPC1RAB9APLA2G1BNFKB1
SCHEMBL1543454 0.78 ALDH1A1 (0.46) ALDH1A1NPC1RAB9APLA2G1BNFKB1
SCHEMBL1543440 0.77 PTPN1 (0.38) ALDH1A1NPC1RAB9APLA2G1BNFKB1
SCHEMBL1542747 0.76 PARP1 (0.41) ALDH1A1HIF1ACYP2C9TSHRHSD17B10
SCHEMBL1543186 0.74 CYP3A4 (0.42) ALDH1A1NPC1RAB9ACYP3A4DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B ALDH1A1 1136/4885NPC1 972/4885RAB9A 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.